Mitrec refers to cephalosporin antibiotics.
Cefapirin has a broad-spectrum bactericidal action against Staphylococcus spp., Streptococcus pyogenes, Pasteurella spp., Proteus mirabilis, Fusobacterium spp., Escherichia coli, Klebsiella spp., Neisseria spp., Pseudo-monas aeruginosa, Enterococcus spp., Salmonella spp., Shigella spp., Haemophilus influenzae, and other pathogenic microorganisms, mainly isolated from subacute and chronic forms of endometritis in cows.
The bactericidal effect of cefapirin consists in inhibiting the synthesis of the cell wall, which causes the destruction of the cytoplasmic membrane and the death of the bacterial cell. The antibiotic is resistant to the action of the penicillinase enzyme and retains its activity under aerobic and anaerobic conditions.
Once Mitrec is administered intrauterinally, cefapirin benzathine easily penetrates from the uterine cavity into the endometrium, where it remains in bactericidal concentration for at least 24 hours. Cefapirin benzathine enters the systemic circulation in small amounts; the maximum concentration of antibiotic in blood plasma within 1 to 2 hours after administration is 0.11 to 0.44 µg/mL. The antibiotic is excreted mainly with urine in an unchanged form and in the form of a metabolite, i. e. deacetylcephapirin.
By the degree of its effect on the animal body, Mitrec refers to low-hazard substances (hazard class 4 as per GOST12.1.007-76).